Current research is exploring therapeutic strategies targeting CD276 and its pathways to enhance anti-tumor immune responses, potentially improving the efficacy of existing treatments or leading to new interventions for CRC patients (81). The gene discussed is CD276; the disease is colorectal carcinoma.